Kevin Brigle, NP
Nurse Practitioner · Richmond, VANPI 1912081571
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,720 of the $165,988 with a category attached, or 65.5%. It is spread thinly across 21 manufacturers, the largest accounting for just 22.7%. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $555.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$38K
- E.r. Squibb & Sons, L.L.C.$26K
- AstraZeneca$20K
- Pfizer$16K
- Johnson & Johnson$16K
- Karyopharm Therapeutics Inc.$14K
- plus $37K from 15 others
What the payments were for
- Consulting fees$24,28615%
- Speaking & faculty fees$108,72065%
- Grants$5,2823%
- Travel & lodging$18,58311%
- Food & beverage$9,0535%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 56 | $37,748 |
| E.r. Squibb & Sons, L.L.C. | 62 | $25,573 |
| AstraZeneca | 40 | $20,279 |
| Pfizer | 18 | $16,241 |
| Johnson & Johnson(2 entities) | 19 | $15,528 |
| Karyopharm Therapeutics Inc. | 27 | $13,893 |
| Bristol Myers Squibb | 17 | $9,065 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $8,894 |
| AbbVie | 12 | $6,110 |
| Legend Biotech USA Inc. | 8 | $2,559 |
| Amgen | 4 | $1,945 |
| Seagen Inc. | 5 | $1,712 |
| Incyte Corporation | 4 | $1,710 |
| Janssen Scientific Affairs, LLC | 6 | $1,122 |
| Beigene, Ltd. | 1 | $1,040 |
| Beigene USA, Inc. | 1 | $900 |
| Genmab U.S., Inc. | 3 | $839 |
| GSK | 1 | $543 |
| Blueprint Medicines Corporation | 1 | $117 |
| Gilead | 1 | $88 |
| Sobi, Inc | 1 | $81 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$165,988 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 197 | $4,286,023 |
| RevlimidLenalidomide | 221 | $4,120,467 |
| Lenalidomide | 261 | $3,493,133 |
| IclusigPonatinib Hcl | 19 | $413,161 |
| VenclextaVenetoclax | 51 | $396,240 |
| TibsovoIvosidenib | 12 | $358,084 |
| BosulifBosutinib | 26 | $352,560 |
| SprycelDasatinib | 17 | $318,789 |
| ImbruvicaIbrutinib | 16 | $256,971 |
| JaypircaPirtobrutinib | 11 | $247,399 |
| Imatinib Mesylate | 54 | $214,914 |
| CalquenceAcalabrutinib Maleate | 12 | $184,783 |
| BrukinsaZanubrutinib | 14 | $184,591 |
| GleevecImatinib Mesylate | 11 | $184,369 |
| NinlaroIxazomib Citrate | 13 | $164,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $25,573 | $4,604,812214 claims |
| Bristol Myers SquibbRevlimid | $9,065 | $4,120,467221 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig, Ninlaro | $8,894 | $577,92032 claims |
| AbbVieVenclexta | $6,110 | $396,24051 claims |
| PfizerBosulif, Eliquis | $16,241 | $384,40056 claims |
| AstraZenecaCalquence | $20,279 | $184,78312 claims |
| Beigene USA, Inc.Brukinsa | $900 | $184,59114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Richmond
- Denese GomesRichmond$126K
- Angelica KubeRichmond$10K
- Kristin CrainRichmond$8K
- Kristin SeiglerRichmond$7K
- Michele CanfieldRichmond$6K
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.